Efficacy and Safety Study of Apixaban for the Treatment o... | NCT00643201

NCT00643201

ID	Type	Description	Link
EUDRACT: 2007-007867-25

Status Module

Name	Class
Pfizer	INDUSTRY

Oversight Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Apixaban	Active Comparator	apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.	Drug: Enoxaparin Drug: warfarin Drug: Placebo for apixaban
Enoxaparin + Warfarin	Experimental	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.	Drug: Placebo for enoxaparin Drug: Placebo for warfarin Drug: apixaban

Name	Type	Description	Arm Group Labels	Other Names
Enoxaparin	Drug	solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.	Apixaban

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment	VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).	Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)

Secondary Outcomes

Measure	Description	Time Frame
Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death	VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.

Eligibility Module

Name	Affiliation	Role
Bristol-Myers Squibb	Bristol-Myers Squibb	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Alabama Clinical Therapeutics, Llc		Birmingham	Alabama	35235	United States
Horizon Research Group, Inc.

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
35570249	Derived	Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16.
33890242	Derived

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Apixaban	apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months. Placebo for enoxaparin: solution, subcutaneous, 1milligram per kilogram (mg/kg) every 12 hours until sham international normalized ratio (INR) greater than, equal to ( ≥) 2. Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Arm/Group Information

ID	Title	Description
BG000	Apixaban	apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months. Placebo for enoxaparin: solution, subcutaneous, 1milligram per kilogram (mg/kg) every 12 hours until sham International normalized ratio (INR) greater than, equal to ( ≥) 2. Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
BG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2. warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Mean

Standard Deviation

years

Title

Denominators

Categories

Title	Measurements
	BG00057.2± 15.98 BG00156.7± 16.01 BG00256.9± 16.00

Age, Customized

Number

participants

Title

Denominators

Categories

Less than (<) 65

Title	Measurements
	BG0001729 BG0011762 BG002

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG0001122 BG0011106 BG002

Race/Ethnicity, Customized

Ethnicity was not collected outside of the United States.

Number

participants

Title

Denominators

Categories

White

Title	Measurements
	BG0002218 BG0012243 BG002

Region of Enrollment

Number

participants

Title

Denominators

Categories

Portugal

Title	Measurements
	BG00010 BG0019 BG002

Qualifying index Venous Thromboembolic Embolism

Both the 2004 and 2008 American College of Chest Physicians (ACCP) recommendations for treatment of venous thromboembolic events (VTE) were used during this study and recommendations were consistent. Participants with provoked and unprovoked index events were summarized. For unprovoked events in participants with certain risk factors and medical conditions, such as cancer, an idiopathic event, presence of pro-thrombotic genotype, or presence of a marker indicative of an increased risk of recurrent thromboembolism treatment for 6 months or longer is supported by the ACCP guidelines.

Number

participants

Title

Denominators

Categories

Provoked Index VTE

Title	Measurements
	BG000272 BG001

Index Event Classification

Participants with events of either deep vein thrombosis (DVT) or pulmonary embolism (PE) were enrolled. If a participant had both DVT and PE, the participant was classified to PE. Each participant was counted once in a category but could be counted in more than one category. An Independent Central Adjudication Committee (ICAC) reviewed participants in a blinded manner. The ICAC included a chairman and independent reviewers who were physicians with experience in vascular medicine and thrombosis. The ICAC adjudicated all index events (proximal DVT and/or PE).

Number

participants

Title

Denominators

Categories

Proximal DVT

Title	Measurements
	BG0001778 BG001

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment

VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).

All randomized participants with a non-missing primary endpoint (n/N: 59/2609; 71/2635, in apixaban, enoxaparin/warfarin, respectively). Intent-to-treat population. Confidence interval (CI) for event rate calculated based on the Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2. Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Units	Counts
Participants	OG0002609 OG0012635

Title

Denominators

Categories

Title	Measurements
	OG0000.0226(0.0169 to 0.0283) OG0010.0269(0.0208 to 0.0331)

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Hypothesis that apixaban was non-inferior to enoxaparin/warfarin therapy in preventing the recurrence of VTE (nonfatal DVT or nonfatal PE)/VTE-related death.	Yanagawa-Tango-Hiejima	For a successful trial; rejection of the null hypotheses for both RR and RD was required.	<0.0001	This is the first test in a sequential testing sequence. p-value calculated based on the Yanagawa-Tango-Hiejima test stratified by index event strata for non-inferiority. Tested at 1-sided α=0.025	Risk Ratio (RR)	0.8390			2-Sided	95	0.5965	1.1802				Yes

Secondary

Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.

All randomized participants with non-missing secondary endpoint (n/N: 84/2609; 104/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.

All randomized participants with non-missing secondary endpoint (n/N: 61/2609; 77/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2. Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding

VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle

Total number of participants in each randomized arm, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 73/2610; 118/2635). Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding

VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).

Total number participants in each treatment group, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 183/2617; 333/2641). Events included as per ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period

DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 22/2608; 35/2633). CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period

PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).

Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 27/2606; 25/2632). CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

Total number of participants in respective treatment groups excluding participants with missing endpoint information. (n/N: 12/2608; 16/2630). CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001

Secondary

Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period

VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).

Total number of participants in respective groups excluding those with missing endpoint information (n/N: 15/2608; 23/2630). CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001

Secondary

Incidence of All-Cause Death During the Intended Treatment Period

Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).

Total number of participants excluding those with missing endpoint (n/N: 41/2608; 52/2630). Events included regardless of whether or not participant received treatment, ie, ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants

All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Total number of participants receiving at least one dose of study drug n/N: 15/2676; 49/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants

Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).

Total number of participants receiving at least one dose of study drug n/N: 115/2676; 261/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Total number of participants receiving at least one dose of study drug n/N: 103/2676; 215/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Total number of participants receiving at least one dose of study drug n/N: 313/2676; 505/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001

Secondary

Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants

Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.

Total number of participants receiving at least one dose of study drug n/N: 402/2676; 676/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.

Posted

Number

95% Confidence Interval

proportion of participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin

Secondary

Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants

Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Total number of participants receiving at least one dose of study drug. Participants were categorized according to the actual treatment received.

Posted

Number

participants

First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months

Secondary

Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests

Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL.

N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.

Posted

Number

participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests

Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN.

N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.

Posted

Number

participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin

Secondary

Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests

Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN.

N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.

Posted

Number

participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests

Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or <LLN; Uric acid High: > 1.5* ULN, or if pre-dose > ULN then use > 2 *pre-dose.

N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.

Posted

Number

participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001	Enoxaparin + Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months

Secondary

Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests

All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.

N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.

Posted

Number

participants

Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)

ID	Title	Description
OG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
OG001

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Apixaban	Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months			417	2,676	1,014	2,676
EG001	Enoxaparin/Warfarin	Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2 warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months			410	2,689	1,207	2,689

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
ANAEMIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0014 affected2,689 at risk
ANAEMIA MEGALOBLASTIC	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ANAEMIA OF CHRONIC DISEASE	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DISSEMINATED INTRAVASCULAR COAGULATION	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
HAEMORRHAGIC ANAEMIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HILAR LYMPHADENOPATHY	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
IRON DEFICIENCY ANAEMIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NEUTROPENIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NORMOCHROMIC NORMOCYTIC ANAEMIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SPLENIC INFARCTION	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
THROMBOCYTOPENIA	Blood and lymphatic system disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0011 affected2,689 at risk
ACUTE MYOCARDIAL INFARCTION	Cardiac disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0012 affected2,689 at risk
ANGINA PECTORIS	Cardiac disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0011 affected2,689 at risk
ANGINA UNSTABLE	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
ATRIAL FIBRILLATION	Cardiac disorders	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0017 affected2,689 at risk
ATRIAL FLUTTER	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ATRIAL TACHYCARDIA	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ATRIAL THROMBOSIS	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ATRIOVENTRICULAR BLOCK	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BRADYCARDIA	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
CARDIAC ARREST	Cardiac disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
CARDIAC FAILURE	Cardiac disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0018 affected2,689 at risk
CARDIAC FAILURE ACUTE	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CARDIAC FAILURE CONGESTIVE	Cardiac disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0012 affected2,689 at risk
CARDIO-RESPIRATORY ARREST	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CARDIOGENIC SHOCK	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
CARDIOMYOPATHY	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CARDIOPULMONARY FAILURE	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CORONARY ARTERY DISEASE	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0015 affected2,689 at risk
DILATATION VENTRICULAR	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
INTRACARDIAC THROMBUS	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
MYOCARDIAL INFARCTION	Cardiac disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
PALPITATIONS	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERICARDIAL HAEMORRHAGE	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERICARDITIS	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PRINZMETAL ANGINA	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RIGHT VENTRICULAR DYSFUNCTION	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SUPRAVENTRICULAR TACHYCARDIA	Cardiac disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
TACHYCARDIA	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VENTRICULAR EXTRASYSTOLES	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VENTRICULAR FIBRILLATION	Cardiac disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
VENTRICULAR HYPOKINESIA	Cardiac disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SICKLE CELL ANAEMIA WITH CRISIS	Congenital, familial and genetic disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
INNER EAR DISORDER	Ear and labyrinth disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
VERTIGO	Ear and labyrinth disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CONJUNCTIVITIS	Eye disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RETINAL HAEMORRHAGE	Eye disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ABDOMINAL DISTENSION	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ABDOMINAL PAIN	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0012 affected2,689 at risk
ABDOMINAL PAIN LOWER	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ABDOMINAL PAIN UPPER	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ABDOMINAL WALL HAEMATOMA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
ABDOMINAL WALL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ASCITES	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
COLITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
COLONIC POLYP	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
CONSTIPATION	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DIAPHRAGMATIC HERNIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DIVERTICULUM	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DUODENAL ULCER HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
DUODENITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DUODENOGASTRIC REFLUX	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DYSPEPSIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
DYSPHAGIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ENTERITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
FLATULENCE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTRIC HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTRIC POLYPS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTRIC ULCER HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTRITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
GASTRITIS EROSIVE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0008 affected2,676 at risk EG00114 affected2,689 at risk
GASTROINTESTINAL HYPOMOTILITY	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTROINTESTINAL ULCER HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTROLITHIASIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GINGIVAL BLEEDING	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HAEMATEMESIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
HAEMATOCHEZIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
HAEMORRHOIDAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HAEMORRHOIDS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
ILEUS PARALYTIC	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
INTESTINAL ISCHAEMIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
INTESTINAL OBSTRUCTION	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
IRRITABLE BOWEL SYNDROME	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LOWER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
MALLORY-WEISS SYNDROME	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
MELAENA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
NAUSEA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
NEUTROPENIC COLITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
OESOPHAGITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PANCREATITIS	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PANCREATITIS ACUTE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PANCREATITIS RELAPSING	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PERITONEAL CYST	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RECTAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
RETROPERITONEAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SMALL INTESTINAL OBSTRUCTION	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TONGUE OEDEMA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
UMBILICAL HERNIA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
UMBILICAL HERNIA, OBSTRUCTIVE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
UPPER GASTROINTESTINAL HAEMORRHAGE	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VOMITING	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ASTHENIA	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
AXILLARY PAIN	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CHEST PAIN	General disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0014 affected2,689 at risk
DEATH	General disorders	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0012 affected2,689 at risk
DEVICE OCCLUSION	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HERNIA OBSTRUCTIVE	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MULTI-ORGAN DISORDER	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MULTI-ORGAN FAILURE	General disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0011 affected2,689 at risk
NON-CARDIAC CHEST PAIN	General disorders	15.0	Non-systematic Assessment	EG0009 affected2,676 at risk EG0016 affected2,689 at risk
OEDEMA PERIPHERAL	General disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0013 affected2,689 at risk
PELVIC MASS	General disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PYREXIA	General disorders	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0011 affected2,689 at risk
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME	General disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CHOLECYSTITIS	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
CHOLECYSTITIS ACUTE	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
CHOLELITHIASIS	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0012 affected2,689 at risk
CHOLESTASIS	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DRUG-INDUCED LIVER INJURY	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HEPATIC CYST	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HEPATIC FAILURE	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
HEPATIC FUNCTION ABNORMAL	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HEPATITIS	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
JAUNDICE CHOLESTATIC	Hepatobiliary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ALLERGY TO ARTHROPOD BITE	Immune system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
AUTOIMMUNE DISORDER	Immune system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BEHCET'S SYNDROME	Immune system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DRUG HYPERSENSITIVITY	Immune system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HYPERSENSITIVITY	Immune system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
ABDOMINAL ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ABDOMINAL WALL ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ABSCESS INTESTINAL	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ABSCESS LIMB	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
APPENDICITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ARTHRITIS BACTERIAL	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BACTERAEMIA	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BRONCHITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0012 affected2,689 at risk
BRONCHITIS BACTERIAL	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BRONCHOPNEUMONIA	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0013 affected2,689 at risk
CARDIAC VALVE VEGETATION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CELLULITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0013 affected2,689 at risk
CELLULITIS ORBITAL	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CLOSTRIDIAL INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CYSTITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CYTOMEGALOVIRUS COLITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DEVICE RELATED INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DIVERTICULITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
ENTEROCOLITIS INFECTIOUS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ERYSIPELAS	Infections and infestations	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0012 affected2,689 at risk
GASTROENTERITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
GENITAL HERPES	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GROIN ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HELICOBACTER GASTRITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HERPES ZOSTER	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
INFECTED SKIN ULCER	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LOCALISED INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LUNG ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LUNG INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MASTOIDITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MYCOBACTERIAL INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MYELITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
OROPHARYNGEAL CANDIDIASIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
OSTEOMYELITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
PERINEAL ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PERITONITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PNEUMOCYSTIS JIROVECI PNEUMONIA	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PNEUMONIA	Infections and infestations	15.0	Non-systematic Assessment	EG00016 affected2,676 at risk EG00112 affected2,689 at risk
PULMONARY TUBERCULOSIS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PURULENT PERICARDITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PYELONEPHRITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
RESPIRATORY TRACT INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
SEPSIS	Infections and infestations	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0015 affected2,689 at risk
SEPTIC SHOCK	Infections and infestations	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0011 affected2,689 at risk
STAPHYLOCOCCAL INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
STAPHYLOCOCCAL SEPSIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TONSILLITIS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
TUBERCULOSIS	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TULARAEMIA	Infections and infestations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
URINARY TRACT INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0008 affected2,676 at risk EG0013 affected2,689 at risk
UROSEPSIS	Infections and infestations	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0010 affected2,689 at risk
VIRAL INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VULVAL ABSCESS	Infections and infestations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ACCIDENTAL OVERDOSE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
ANKLE FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
CERVICAL VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CONTUSION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
DRUG ADMINISTRATION ERROR	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
EXCORIATION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
EXTRADURAL HAEMATOMA	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
FACE INJURY	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
FACIAL BONES FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
FALL	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
FEMUR FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
HEAD INJURY	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HIP FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HUMERUS FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
INCORRECT DOSE ADMINISTERED	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
JOINT DISLOCATION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
LOWER LIMB FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LUMBAR VERTEBRAL FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
MENISCUS LESION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
OVERDOSE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG00015 affected2,676 at risk EG00111 affected2,689 at risk
PELVIC FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PERIPHERAL ARTERIAL REOCCLUSION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
POST PROCEDURAL HAEMORRHAGE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
RADIUS FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RENAL HAEMATOMA	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
SPINAL COLUMN INJURY	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SPINAL COMPRESSION FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
SUBCUTANEOUS HAEMATOMA	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
SUBDURAL HAEMORRHAGE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TOXICITY TO VARIOUS AGENTS	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
TRAUMATIC HAEMATOMA	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
UPPER LIMB FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VASCULAR PSEUDOANEURYSM	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
WRIST FRACTURE	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ALANINE AMINOTRANSFERASE INCREASED	Investigations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
COAGULATION TIME PROLONGED	Investigations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GAMMA-GLUTAMYLTRANSFERASE INCREASED	Investigations	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HEPATIC ENZYME INCREASED	Investigations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
INTERNATIONAL NORMALISED RATIO INCREASED	Investigations	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0017 affected2,689 at risk
LIVER FUNCTION TEST ABNORMAL	Investigations	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DEHYDRATION	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0013 affected2,689 at risk
DIABETES MELLITUS	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
FAILURE TO THRIVE	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GOUT	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HYPERGLYCAEMIA	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
HYPERKALAEMIA	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HYPOKALAEMIA	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HYPONATRAEMIA	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG0004 affected2,676 at risk EG0010 affected2,689 at risk
ARTHRALGIA	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0013 affected2,689 at risk
BACK PAIN	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
COSTOCHONDRITIS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
FRACTURE MALUNION	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GOUTY ARTHRITIS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GROIN PAIN	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
INTERVERTEBRAL DISC PROTRUSION	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
JOINT EFFUSION	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
LIGAMENT DISORDER	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
LIMB DISCOMFORT	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
MUSCLE HAEMORRHAGE	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
MUSCULOSKELETAL CHEST PAIN	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0011 affected2,689 at risk
MUSCULOSKELETAL PAIN	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
MYALGIA	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0012 affected2,689 at risk
PATHOLOGICAL FRACTURE	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
POLYMYALGIA RHEUMATICA	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PSEUDARTHROSIS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ROTATOR CUFF SYNDROME	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
SPINAL OSTEOARTHRITIS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
SYNOVIAL CYST	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SYSTEMIC LUPUS ERYTHEMATOSUS	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
BASAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0013 affected2,689 at risk
BENIGN OVARIAN TUMOUR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BILE DUCT CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0010 affected2,689 at risk
BLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
BLADDER PAPILLOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BLADDER TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BONE NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BRAIN CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BREAST CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0012 affected2,689 at risk
BREAST CANCER RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
BRONCHIAL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
CERVIX CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CERVIX NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CHOLESTEATOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
COLON CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0012 affected2,689 at risk
COLON CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
COLON NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
COLORECTAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
ENDOCRINE NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ESSENTIAL THROMBOCYTHAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GALLBLADDER CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTRIC CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTRIC CANCER RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTROINTESTINAL CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GASTROINTESTINAL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTROINTESTINAL STROMAL TUMOUR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GASTROINTESTINAL TRACT ADENOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GLIOBLASTOMA MULTIFORME	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HEPATIC CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
INTESTINAL ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
LEIOMYOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LUNG ADENOCARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
LUNG CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
LUNG NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0016 affected2,689 at risk
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MALIGNANT NEOPLASM PROGRESSION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
MALIGNANT PERITONEAL NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
METASTASES TO ABDOMINAL CAVITY	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
METASTASES TO BONE	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
METASTASES TO CENTRAL NERVOUS SYSTEM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
METASTASES TO LIVER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
METASTASES TO LUNG	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
METASTASES TO PERITONEUM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
METASTASIS	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
METASTATIC CARCINOMA OF THE BLADDER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
METASTATIC NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
METASTATIC RENAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MYELODYSPLASTIC SYNDROME	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NEOPLASM MALIGNANT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
NEUROENDOCRINE TUMOUR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
NON-HODGKIN'S LYMPHOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
OESOPHAGEAL CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ONCOCYTOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
OVARIAN CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
OVARIAN CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PANCREATIC CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0014 affected2,689 at risk
PANCREATIC CARCINOMA METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0013 affected2,689 at risk
PANCREATIC CARCINOMA RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PANCREATIC CARCINOMA STAGE IV	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PANCREATIC NEUROENDOCRINE TUMOUR	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PARAPROTEINAEMIA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PELVIC NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
POLYCYTHAEMIA VERA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PROSTATE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0013 affected2,689 at risk
PROSTATE CANCER RECURRENT	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RECTAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RECTOSIGMOID CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RENAL CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
RENAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
SALIVARY GLAND CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SMALL CELL LUNG CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SQUAMOUS CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0012 affected2,689 at risk
TESTIS CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
THYROID CANCER METASTATIC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
THYROID NEOPLASM	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TRANSITIONAL CELL CARCINOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
TUMOUR ULCERATION	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
UTERINE CANCER	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
UTERINE LEIOMYOMA	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CAROTID ARTERY STENOSIS	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CEREBRAL HAEMORRHAGE	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
CEREBRAL INFARCTION	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
CEREBROVASCULAR ACCIDENT	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0012 affected2,689 at risk
CERVICOBRACHIAL SYNDROME	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
COMA	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
COMPLEX REGIONAL PAIN SYNDROME	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CONVULSION	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
ENCEPHALOPATHY	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GRAND MAL CONVULSION	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
HAEMORRHAGE INTRACRANIAL	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HAEMORRHAGIC STROKE	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
HEADACHE	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
ISCHAEMIC STROKE	Nervous system disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0015 affected2,689 at risk
LACUNAR INFARCTION	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MIGRAINE	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MULTIPLE SCLEROSIS	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
NERVOUS SYSTEM DISORDER	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
NEURALGIA	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NEURITIS	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
NEUROPATHY PERIPHERAL	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
PARAESTHESIA	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PARAPLEGIA	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERONEAL NERVE PALSY	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
POLYNEUROPATHY	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PRESYNCOPE	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SCIATICA	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
SPINAL CORD COMPRESSION	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
SUBARACHNOID HAEMORRHAGE	Nervous system disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
SYNCOPE	Nervous system disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0013 affected2,689 at risk
THALAMIC INFARCTION	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TOXIC ENCEPHALOPATHY	Nervous system disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TRANSIENT ISCHAEMIC ATTACK	Nervous system disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
ABORTION SPONTANEOUS	Pregnancy, puerperium and perinatal conditions	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PREGNANCY	Pregnancy, puerperium and perinatal conditions	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0012 affected2,689 at risk
ADJUSTMENT DISORDER	Psychiatric disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ALCOHOL ABUSE	Psychiatric disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ALCOHOLISM	Psychiatric disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ANXIETY	Psychiatric disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0012 affected2,689 at risk
APATHY	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BIPOLAR DISORDER	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CONFUSIONAL STATE	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
DEPRESSION	Psychiatric disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0013 affected2,689 at risk
DEPRESSION SUICIDAL	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
MENTAL DISORDER	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PANIC ATTACK	Psychiatric disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
SUICIDAL IDEATION	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
TIC	Psychiatric disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
GLOMERULONEPHRITIS CHRONIC	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
GLOMERULONEPHRITIS MEMBRANOPROLIFERATIVE	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HAEMATURIA	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG00113 affected2,689 at risk
HAEMORRHAGE URINARY TRACT	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HYDRONEPHROSIS	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
NEPHROLITHIASIS	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0011 affected2,689 at risk
OLIGURIA	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RENAL COLIC	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RENAL CYST HAEMORRHAGE	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RENAL FAILURE	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0012 affected2,689 at risk
RENAL FAILURE ACUTE	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0013 affected2,689 at risk
RENAL FAILURE CHRONIC	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RENAL IMPAIRMENT	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
URINARY BLADDER HAEMORRHAGE	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
URINARY RETENTION	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
URINARY TRACT OBSTRUCTION	Renal and urinary disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ENDOMETRIAL HYPERTROPHY	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
MENORRHAGIA	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
METRORRHAGIA	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
OVARIAN CYST	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
UTERINE HAEMORRHAGE	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0012 affected2,689 at risk
UTERINE POLYP	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
VAGINAL HAEMORRHAGE	Reproductive system and breast disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
ACUTE RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
ADENOIDAL HYPERTROPHY	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ALLERGIC GRANULOMATOUS ANGIITIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ASTHMA	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0010 affected2,689 at risk
ASTHMATIC CRISIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ATELECTASIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
BRONCHOSTENOSIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CHRONIC OBSTRUCTIVE PULMONARY DISEASE	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0009 affected2,676 at risk EG0016 affected2,689 at risk
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0009 affected2,676 at risk EG0015 affected2,689 at risk
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0012 affected2,689 at risk
HAEMOPTYSIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
INTERSTITIAL LUNG DISEASE	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
LUNG CONSOLIDATION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PLEURAL EFFUSION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0003 affected2,676 at risk EG0017 affected2,689 at risk
PLEURISY	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PLEURITIC PAIN	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0005 affected2,676 at risk EG0012 affected2,689 at risk
PNEUMONIA ASPIRATION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PNEUMONITIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PNEUMOTHORAX	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0013 affected2,689 at risk
PULMONARY ALVEOLAR HAEMORRHAGE	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PULMONARY AMYLOIDOSIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PULMONARY ARTERIAL HYPERTENSION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PULMONARY EMBOLISM	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG00024 affected2,676 at risk EG00138 affected2,689 at risk
PULMONARY HYPERTENSION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
PULMONARY INFARCTION	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0013 affected2,689 at risk
PULMONARY MASS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PULMONARY OEDEMA	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
RESPIRATORY DISTRESS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RESPIRATORY FAILURE	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
SLEEP APNOEA SYNDROME	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
CAPILLARITIS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
CUTANEOUS VASCULITIS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DERMATITIS ALLERGIC	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
DIABETIC FOOT	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
DRUG ERUPTION	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ECCHYMOSIS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ECZEMA	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
HAEMORRHAGE SUBCUTANEOUS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PURPURA	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
RASH	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
SKIN LESION	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
SKIN NECROSIS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SKIN ULCER	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
STASIS DERMATITIS	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
URTICARIA	Skin and subcutaneous tissue disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PREGNANCY OF PARTNER	Social circumstances	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ANGIODYSPLASIA	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
AORTIC ANEURYSM	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
AORTIC RUPTURE	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ARTERIAL THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
ARTERIOSCLEROSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
DEEP VEIN THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG00020 affected2,676 at risk EG00133 affected2,689 at risk
EMBOLISM VENOUS	Vascular disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
FEMORAL ARTERY ANEURYSM	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
HAEMATOMA	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0014 affected2,689 at risk
HYPERTENSION	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
HYPERTENSIVE CRISIS	Vascular disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0010 affected2,689 at risk
HYPOTENSION	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
INTRA-ABDOMINAL HAEMATOMA	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
JUGULAR VEIN THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
ORTHOSTATIC HYPOTENSION	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERIPHERAL ARTERY ANEURYSM	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
PERIPHERAL ARTERY STENOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
PERIPHERAL ISCHAEMIA	Vascular disorders	15.0	Non-systematic Assessment	EG0002 affected2,676 at risk EG0011 affected2,689 at risk
PERIPHERAL VASCULAR DISORDER	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
SHOCK HAEMORRHAGIC	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0011 affected2,689 at risk
TEMPORAL ARTERITIS	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
THROMBOPHLEBITIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0013 affected2,689 at risk
THROMBOPHLEBITIS SUPERFICIAL	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0012 affected2,689 at risk
VENA CAVA THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0000 affected2,676 at risk EG0011 affected2,689 at risk
VENOUS STENOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk
VENOUS THROMBOSIS	Vascular disorders	15.0	Non-systematic Assessment	EG0006 affected2,676 at risk EG0010 affected2,689 at risk
VENOUS THROMBOSIS LIMB	Vascular disorders	15.0	Non-systematic Assessment	EG0001 affected2,676 at risk EG0010 affected2,689 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
CONSTIPATION	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG00073 affected2,676 at risk EG00187 affected2,689 at risk
DIARRHOEA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG000100 affected2,676 at risk EG001106 affected2,689 at risk
NAUSEA	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG00081 affected2,676 at risk EG001106 affected2,689 at risk
VOMITING	Gastrointestinal disorders	15.0	Non-systematic Assessment	EG00050 affected2,676 at risk EG00169 affected2,689 at risk
FATIGUE	General disorders	15.0	Non-systematic Assessment	EG00058 affected2,676 at risk EG00150 affected2,689 at risk
OEDEMA PERIPHERAL	General disorders	15.0	Non-systematic Assessment	EG00093 affected2,676 at risk EG001111 affected2,689 at risk
PYREXIA	General disorders	15.0	Non-systematic Assessment	EG00054 affected2,676 at risk EG00156 affected2,689 at risk
BRONCHITIS	Infections and infestations	15.0	Non-systematic Assessment	EG00051 affected2,676 at risk EG00156 affected2,689 at risk
NASOPHARYNGITIS	Infections and infestations	15.0	Non-systematic Assessment	EG000104 affected2,676 at risk EG00198 affected2,689 at risk
URINARY TRACT INFECTION	Infections and infestations	15.0	Non-systematic Assessment	EG00092 affected2,676 at risk EG00182 affected2,689 at risk
CONTUSION	Injury, poisoning and procedural complications	15.0	Non-systematic Assessment	EG00048 affected2,676 at risk EG00197 affected2,689 at risk
ALANINE AMINOTRANSFERASE INCREASED	Investigations	15.0	Non-systematic Assessment	EG00030 affected2,676 at risk EG001105 affected2,689 at risk
BLOOD CREATINE PHOSPHOKINASE INCREASED	Investigations	15.0	Non-systematic Assessment	EG00033 affected2,676 at risk EG00178 affected2,689 at risk
GAMMA-GLUTAMYLTRANSFERASE INCREASED	Investigations	15.0	Non-systematic Assessment	EG00038 affected2,676 at risk EG00156 affected2,689 at risk
HYPERCHOLESTEROLAEMIA	Metabolism and nutrition disorders	15.0	Non-systematic Assessment	EG00028 affected2,676 at risk EG00155 affected2,689 at risk
ARTHRALGIA	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG00074 affected2,676 at risk EG00184 affected2,689 at risk
BACK PAIN	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG00080 affected2,676 at risk EG00187 affected2,689 at risk
PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	15.0	Non-systematic Assessment	EG000119 affected2,676 at risk EG001130 affected2,689 at risk
DIZZINESS	Nervous system disorders	15.0	Non-systematic Assessment	EG00066 affected2,676 at risk EG00169 affected2,689 at risk
HEADACHE	Nervous system disorders	15.0	Non-systematic Assessment	EG000169 affected2,676 at risk EG001167 affected2,689 at risk
HAEMATURIA	Renal and urinary disorders	15.0	Non-systematic Assessment	EG00041 affected2,676 at risk EG00191 affected2,689 at risk
COUGH	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG00061 affected2,676 at risk EG00158 affected2,689 at risk
DYSPNOEA	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG00064 affected2,676 at risk EG00173 affected2,689 at risk
EPISTAXIS	Respiratory, thoracic and mediastinal disorders	15.0	Non-systematic Assessment	EG00077 affected2,676 at risk EG001144 affected2,689 at risk
HAEMATOMA	Vascular disorders	15.0	Non-systematic Assessment	EG00034 affected2,676 at risk EG00172 affected2,689 at risk
HYPERTENSION	Vascular disorders	15.0	Non-systematic Assessment	EG00070 affected2,676 at risk EG00168 affected2,689 at risk

ID	Term
D013927	Thrombosis
D016769	Embolism and Thrombosis
D014652	Vascular Diseases
D002318	Cardiovascular Diseases

ID	Term
D006495	Heparin, Low-Molecular-Weight
D006493	Heparin
D006025	Glycosaminoglycans
D011134	Polysaccharides
D002241	Carbohydrates
D015110	4-Hydroxycoumarins
D003374	Coumarins
D001578	Benzopyrans
D011714	Pyrans
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring